Evidence for Altered Desipramine Disposition in Methadone-Maintained Patients Treated for Cocaine Abuse

References

• Cocaine: Pharmacology, Effects, and Treatment of Abuse. NIDA Research Monograph 50, J. Grabowski. U.S. Government Printing Office, Washington, D.C. 1984
   Google Scholar
• Gawin F. H., Kleber H. D., Byck R., Rounsaville B. J., Kosten T. R., Jatlow P. I., Morgan C. Despiramine facilitation of initial cocaine abstinence. Arch. Gen. Psychiatry 1989; 46: 117–121
   PubMed Web of Science ®Google Scholar
• Kosten T. R. Pharmacotherapeutic interventions for cocaine abuse: Matching patients to treatments. J. Nerv. Menu Dis. 1989; 177: 379–389
   PubMed Web of Science ®Google Scholar
• Arndt I., Dorozynsky L., McLellan A. T., Woody G., O'Brien C. P. Desipramine treatment of cocaine abuse in methadone maintained patients. Proceedings of the Committee on Problems of Drug Dependence. 1989, In Press
   Google Scholar
• Weddington W. W., Brown B. S., Haertzen C. A., Hess J. M., Mahaffey J. R., Kolar A. F., Jaffee J. H. Amantadine and desipramine for treatment of cocaine dependence. Proceedings of the Committee on Problems of Drug Dependence. 1989, In Press
   Google Scholar
• Kosten T. R., Rounsaville B. J., Kleber H. D. A 2.5 year follow-up of cocaine use among treated opioid addicts: Have our treatments helped?. Arch. Gen. Psychiatry 1987; 44: 281–284
   PubMed Web of Science ®Google Scholar
• Kosten T. R., Schumann B., Wright D. R., Carney M. K., Gawin F. H. A pilot study using desipramine for cocaine abusing methadone maintenance patients. J. Clin. Psychiatry 1987; 48(11)442–444
   PubMed Web of Science ®Google Scholar
• Nelson J. C, Jatlow P. I. Neuroleptic effect on desipramine steady-state plasma concentrations. Am. J. Psychiatry 1980; 137: 1232–1234
   PubMed Web of Science ®Google Scholar
• Liu S. J., Wang R. I. Increased analgesia and alterations in distribution and metabolism of methadone by desipramine in the rat. J. Pharm. Exp. Ther. 1975; 195: 94–104
   PubMed Web of Science ®Google Scholar
• Steiner E., Dumont E., Spina E., Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin. Pharmacol. Ther. 1988; 43: 577–581
   PubMed Web of Science ®Google Scholar
• Jandhyala B. S., Steenberg M. L., Perel J. M. Effects of several tricyclic antidepressants on the hemodynamics and myocardial contractility of the anesthetized dogs. Eur. J. Pharmacol. 1977; 42: 403–410
   PubMed Web of Science ®Google Scholar
• Potter W. Z., Calil H. M., Manian A. A. Hydroxylated metabolites of tricyclic antidepressant: Preclinical assessment of activity. Biol. Psychiatry 1979; 14: 6X11–613
   Web of Science ®Google Scholar
• Javaid J. L., Perel J. M., Davis J. M. Inhibition of biogenic amines uptake by imipramine, desipramine, 2-OH-imipramine and 2-OH-desipramine in rat brain. Life Sci. 1979; 24: 21–28
   PubMed Web of Science ®Google Scholar
• Wilkerson R. D. Antiarrhythmic effects of tricyclic antidepressant drugs in ouabain-induced arrhythmias in the dog. J. Pharmacol. Exp. Ther. 1978; 205: 666–674
   PubMed Web of Science ®Google Scholar
• Nelson J. C, Mazure C, Jadow P. I. Antidepressant activity of 2-hydroxydesipramine. Clin. Pharm. Ther. 1988; 44: 283–288
   PubMed Web of Science ®Google Scholar
• Potter W. Z., Calil H. M., Sutfin T. A. Active metabolites of imipramine and desipramine in man. Clin. Pharmacol. Ther. 1982; 31: 393–401
   PubMed Web of Science ®Google Scholar
• Bock J. L., Nelson J. C, Gray S., Jatlow P. I. Desipramine hydroxylation: Variability and effect of antipsychotic drugs. Clin. Pharmacol. Ther. 1983; 33: 190–197
   Web of Science ®Google Scholar
• DeVane C. L., Savett M., Jusko W. J. Desipramine and 2-hydroxydesipramine pharmacokinetics in normal volunteers. Eur. J. Clin. Pharmacol. 1981; 19: 61–64
   PubMed Web of Science ®Google Scholar
• Nelson J. C, Jatlow P. I., Quinlan D. M. Desipramine plasma concentration and antidepressant response. Arch. Gen. Psychiatry 1982; 39: 1419–1422
   PubMed Web of Science ®Google Scholar
• Proelss H. F., Logman H. J., Miles D. G. High performance liquid chromatographic simultaneous determination of commonly used antidepressants. Clin. Chem. 1978; 24: 1948–1953
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Taylor J. F., Casey A. F., Hassan M. M. A. The biotransformation of methadone in man: Synthesis and identification of a major metabolite. J. Pharm. Pharmacol. 1968; 20: 754–762
   PubMed Web of Science ®Google Scholar
• Pohland A., Boaz H. E., Sullivan H. R. Synthesis and identification of metabolites resulting from the biotransformation of d, l-methadone in man and in the rat. J. Med. Chem. 1971; 14: 194–197
   PubMed Web of Science ®Google Scholar
• Baselt R. C, Casarett L. J. Biliary and urinary elimination of methadone and its metabolites in the rat. Biochem. Pharmacol. 1972; 21: 2705–2712
   Web of Science ®Google Scholar
• Baselt R. C, Bickel M. H. Biliary excretion of methadone by the rat: Identification of a parahydroxylated major metabolite. Biochem. Pharmacol. 1973; 22: 3117–3120
   PubMed Web of Science ®Google Scholar
• Gram L. F., Overo K. F. Drug interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br. J. Med. 1972; 1: 463–465
   PubMed Web of Science ®Google Scholar
• Nelson J. C, Price L. H., Jatlow P. I. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. Am. J. Psychiatry 1986; 143: 1151–1154
   PubMed Web of Science ®Google Scholar
• Lemberger L., Kuntzman R., Conney A. H., Burns J. J. Metabolism of tyramine to dopamine by liver microsomes. J. Pharmacol. Exp. Ther. 1965; 150: 292–297
   PubMed Web of Science ®Google Scholar
• Nelson J. C, Jatlow P. I. Nonlinear desipramine kinetics: Prevalence and importance. Clin. Pharmacol. Ther. 1987; 41: 666–670
   PubMed Web of Science ®Google Scholar